Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis

Journal of Psychopharmacology

Volumn 23, Issue 5, 2009, Pages 539-550

  Omori, I M ^a   Watanabe, N ^a   Nakagawa, A ^b   Akechi, T ^a   Cipriani, A ^c   Barbui, C ^c   McGuire, H ^d   Churchill, R ^d   Furukawa, T A ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF VERONA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressive agents; Fluvoxamine; Major depressive disorder; Meta analysis

Indexed keywords

AMINEPTINE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; ANOREXIA; ANXIETY; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FLUVOXAMINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67449159255     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089876     Document Type: Article

References (54)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Washington, DC: American Psychiatric Press.
2. American Psychiatric Association (2000) Practice guideline for the tratment of patients with major depressive disorder. Am J Psychiatry 157: 1-45 [revision].
3. Anderson IM., (1998) SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7 (Suppl. 1). 11-17.
4. Anderson IM., Edwards JG., (2001) Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. Adv Psychiatric Treat 7: 170-180. (Pubitemid 32927147)
5. Anderson IM., Nutt DJ., Deakin JF., (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14: 3-20. (Pubitemid 30156533)
6. Arroll B., Macgillivray S., Ogston S., Reid I., Sullivan F., Williams B., (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449 - 456. (Pubitemid 41512663)
7. Barbui C., Cipriani A., Brambilla P., Hotopf M., (2004)-Wish bias- in antidepressant drug trials? J Clin Psychopharmacol 24: 126-130.
8. Barbui C., Furukawa TA., Cipriani A., (2008) Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. Can Med Assoc J 178: 296-305. (Pubitemid 351212875)
9. Barbui C., Hotopf M., Freemantle N., Boynton J., Churchill R., Eccles MP., (2000) Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev: CD002791.
10. Buchkowsky SS., Jewesson PJ., (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38: 579-585. (Pubitemid 38352217)
11. Burton SW., (1991) A review of fluvoxamine and its uses in depression. Int Clin Psychopharmacol 6 (Suppl. 3). 1-17, discussion 17-21.
12. Cipriani A., Barbui C., Brambilla P., Furukawa TA., Hotopf M., Geddes J.R., (2006) Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry 67: 850-864. (Pubitemid 44049083)
13. Ciuna A., Andretta M., Corbari L., Levi D., Mirandola M., Sorio A., (2004) Are we going to increase the use of antidepressants up to that of benzodiazepines?. Eur J Clin Pharmacol 60: 629-634. (Pubitemid 40064595)
14. Claassen V., Davies JE., Hertting G., Placheta P., (1977) Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 60: 505-516. (Pubitemid 8149535)
15. Edwards JG., Anderson I., (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57: 507-533. (Pubitemid 29196919)
16. Egger M., Davey Smith G., Schneider M., Minder C., (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
17. Ellis P., (2004) Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 38: 389-407. (Pubitemid 39029045)
18. Fuller RW., Wong DT., (1987) Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol 7: 36S-43S. (Pubitemid 18014274)
19. Furukawa TA., Akechi T., Azuma H., Okuyama T., Higuchi T., (2007a) Evidence-Based Guidelines for Interpretation of the Hamilton Rating Scale for Depression. J Clin Psychopharmacol 27: 531-534. (Pubitemid 47415066)
20. Furukawa TA., Barbui C., Cipriani A., Brambilla P., Watanabe N., (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 59: 7-10. (Pubitemid 41797469)
21. Furukawa TA., Cipriani A., Barbui C., Brambilla P., Watanabe N., (2005) Imputing response rates from means and standard deviations in meta-analysis. Int Clin Psychopharmacol 20: 49-52. (Pubitemid 40105550)
22. Furukawa TA., Guyatt GH., Griffith LE., (2002) Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 31: 72-76. (Pubitemid 34284903)
23. Furukawa TA., Watanabe N., Omori IM., Montori VM., Guyatt GH., (2007b) Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 297: 468-470. (Pubitemid 46220797)
24. www.effectivehealthcare.ahrq.gov/reports/final.cfm
25. Geddes J.R., Freemantle N., Mason J., Eccles MP., Boynton J., (2000) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depressive disorder. Cochrane Database Syst Rev: CD001851.
26. Greenberg PE., Birnbaum HG., (2005) The economic burden of depression in the US: societal and patient perspectives. Expert Opin Pharmacother 6: 369-376. (Pubitemid 40521074)
27. Greenberg PE., Kessler RC., Birnbaum HG., Leong SA., Lowe SW., Berglund PA., (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64: 1465-1475. (Pubitemid 41270106)
28. Guaiana G., Andretta M., Corbari L., Mirandola M., Sorio A., D'Avanzo B., (2005) Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry 66: 750-755. (Pubitemid 40942422)
29. Guaiana G., Barbui C., Hotopf M., (2003) Amitriptyline versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev: CD004186.
30. Hamilton M., (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
31. Hammad TA., Laughren T., Racoosin J., (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63: 332-339. (Pubitemid 43345358)
32. Hansen RA., Gartlehner G., Lohr KN., Gaynes BN., Carey TS., (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143: 415-426. (Pubitemid 41341413)
33. Harris B., Szulecka TK., Anstee JA., (1991) Fluvoxamine versus amitriptyline in depressed hospital out-patients: a multicentre double-blind comparative trial. British Journal of Clinical Research 2: 89-99.
34. JP Higgins., S Green., (eds) (2005) Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Chichester: John Wiley & Sons Ltd.
35. Kadusevicius E., Mikucionyte L., Maciulaitis R., Milvidaite I., Sveikata A., (2006) Trends in the consumption of antidepressant drugs in Lithuania in 2002-2004. Medicina (Kaunas) 42: 1020-1029.
36. Kavoussi RJ., Hauger RL., Coccaro EF., (1999) Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. Biol Psychiatry 45: 295-299. (Pubitemid 29100034)
37. Kostiukova EG., Granenov GM., Andreichik LA., Serditov OV., Mosolov SN., (2003) Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital. Zh Nevrol Psikhiatr Im S S Korsakova 103: 24-29.
38. Lawrenson RA., Tyrer F., Newson RB., Farmer RD., (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59: 149-157. (Pubitemid 30317431)
39. Mackay FJ., Dunn NR., Wilton LV., (1997) A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 6: 235-246. (Pubitemid 27414426)
40. Montejo-Gonzalez AL., Llorca G., Izquierdo JA., (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176-194. (Pubitemid 27514710)
41. Montgomery SA., Asberg M., (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382 - 389. (Pubitemid 9136500)
42. Mottram P., Wilson K., Strobl J., (2006) Antidepressants for depressed elderly. Cochrane Database Syst Rev: CD003491.
43. NICE (2004) Depression: Management of Depression in Primary and Secondary Care. London: National Institute for Clinical Excellence.
44. Perlis RH., Perlis CS., Wu Y., Hwang C., Joseph M., Nierenberg AA., (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162: 1957-1960. (Pubitemid 41428627)
45. Puech A., Montgomery SA., Prost JF., Solles A., Briley M., (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108. (Pubitemid 27286559)
46. Remick RA., Reesal R., Oakander M., Allen J., Claman J., Ramirez CE., (1994) Comparison of fluvoxamine and amitriptyline in depressed outpatients. Curr Ther Res Clin Exp 55: 243-250. (Pubitemid 24134802)
47. Smith D., Dempster C., Glanville J., Freemantle N., Anderson I., (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396-404. (Pubitemid 34499333)
48. Taylor MJ., Freemantle N., Geddes J.R., Bhagwagar Z., (2006) Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 63: 1217-1223. (Pubitemid 44708080)
49. The Nordic Cochrane Centre (2003) Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Cochrane Collaboration.
50. US Department of Heath and Human Services: Agency for Health Care Policy and Research (1993) Depression Guideline Panel. Clinical Practice Guideline: Depression in Primary Care 2: Treatment of Major Depression. Vol. Rockville, MD: AHCPR Publication 93-0551.
51. Ware MR., (1997) Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 58 (Suppl. 5). 15-23. (Pubitemid 27255353)
52. Watanabe N; .,Omori IM; .,Nakagawa A; .,Cipriani A; .,Barbui C; .,McGuire H; ., (in press) Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis. J Clin Psychiatry.
53. http://www.who.int/healthinfo/bodgbd2002/en/index.html
54. Williams JW., Mulrow CD., Chiquette E., Noel PH., Aguilar C., Cornell J., (2000) A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 132: 743-756. (Pubitemid 30244176)